Invited commentary.
Thomas
Stuart P
SP
Department of Cardiology, Westmead Hospital and University of Sydney, Westmead, New South Wales 2145, Australia. stuartpt@yahoo.com
D000367:Age Factors; D000638:Amiodarone / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D002303:Cardiac Output, Low / Q000097:blood / Q000150:complications; D015897:Comorbidity; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000097:blood / Q000601:surgery*; D019918:Heart Valve Prosthesis Implantation; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D011183:Postoperative Complications / Q000097:blood* / Q000175:diagnosis; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000188:drug therapy
D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D020097:Natriuretic Peptide, Brain; D000638:Amiodarone